By John Carroll Bayer CEO Marijn Dekkers recently sat down with Bloomberg and dropped a few tantalizing hints about his idea of the ideal takeover target. While Dekkers declined to speculate on a possible short list of candidates, the CEO also insisted that the pharma giant’s pipeline was in fine shape, making an M&A deal …
By Tracy Staton Bayer’s incoming CEO Marijn Dekkers (photo) has access to money–and he’s willing to spend it. As Dekkers prepares to take over from current Bayer chief Werner Wenning (photo) this Friday, he told reporters that he’s prepared to spend up to $23 billion to beef up the company’s healthcare business (and its GMO seeds business, too, but that’s …
By Maureen Martino Los Angeles-based Kythera Biopharmaceuticals has landed a $373 million licensing deal with Bayer Healthcare’s dermatology unit Intendis. The group gets rights to Kythera’s lead product candidate, ATX-101, outside the U.S. and Canada. Kythera will receive an upfront payment of $43 million and may be eligible to receive up to $330 million in …
